AgeneBio is a Baltimore-based biopharmaceutical company dedicated to discovering and developing innovative therapeutics for neurological and psychiatric conditions. With a mission to improve the lives of patients and their families, their lead clinical program focuses on the prevention of Alzheimer's dementia.
Through their research and development efforts, AgeneBio aims to provide effective treatments for patients at risk of developing neurological disorders, such as Alzheimer's disease, autism, and schizophrenia, ultimately benefiting society as a whole.
Generated from the website